Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Home
R&D
Page 3
R&D
Featured posts
Latest
Featured posts
Most popular
7 days popular
By review score
Random
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
FDA orphan drug and rare pediatric disease designations granted to Arbor Biotechnologies’ primary hyperoxaluria type 1 treatment
Relmada Therapeutics acquires potential Tourette syndrome therapy from Asarina Pharma
Vanda Pharmaceuticals and AnaptysBio announce global license agreement for Generalized Pustular Psoriasis treatment
FDA Orphan Drug Designation granted to NMD670 for Charcot-Marie-Tooth disease
6th January 2025
Orion and Abilita Therapeutics to develop innovative antibody therapeutics
20th December 2024
Conduit Pharmaceuticals partners with Sarborg to leverage AI and cybernetics to...
16th December 2024
Datopotamab deruxtecan granted Breakthrough Therapy Designation in U.S. for patients with...
13th December 2024
Tolebrutinib designated Breakthrough Therapy by FDA for non-relapsing secondary progressive multiple...
13th December 2024
Two combination vaccine candidates for prevention of influenza and COVID-19 granted...
12th December 2024
Cancer Research Horizons and Diamond Light Source establish drug discovery partnership
10th December 2024
Johnson & Johnson licenses novel inflammatory disease target from Mestag Therapeutics
9th December 2024
Muna Therapeutics and GSK to accelerate development of novel treatments for...
6th December 2024
Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation to advance small molecule...
6th December 2024
1
2
3
4
...
53
Page 3 of 53
News
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
AbbVie and Xilio Therapeutics, a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, have announced a collaboration and...
Duchenne muscular dystrophy market to reach $5.2 billion in 7MM by 2033, forecasts GlobalData
14th February 2025
The Duchenne muscular dystrophy (DMD) market across the seven major markets (7MM*) is set to grow from $2.3 billion in 2023 to $5.2 billion...
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
13th February 2025
Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a...